Applicants: Eligible applicants must qualify as a business based and operating in the U.S. They may have sub-awards to universities, but the primary recipient will be the company.
Matching: Recipients are required to match the value of the award in doing work to commercialze the product in a way consistent with being used on long space flights. Sources must be non-federal and private sector investment, which includes in-kind, is preferred. For more detailed information please follow this link.
Use of Funds: All TRISH funds are intended to be used to move the product along the commercialization path in parallel with spaceflight applications and to be spent on technical work, clinical proof of concept, etc., but not for “business activities” (e.g., a “market study”, patent prosecution, FDA documentation, etc.). Matched resources/funds can be used for "business activities". For more detailed information please follow this link.
Intellectual Property (IP): The company retains IP ownership rights, with “walk-in” and “use” terms consistent with the U.S. Federal Government’s SBIR program.
Invoicing: Awardees must invoice on a reimbursement basis.
Provisions: All grant awards are subject to the provisions detailed in 14 CFR 1274 (i.e., for commercial firms).
Reporting: Reporting requirements vary by award type and are as follows:
Validation Award reporting requirements: The PI shall submit a Quarterly Technical Progress Report within 15 calendar days at the end of each quarter, followed by a Final Technical Report. The Final Technical Report shall be submitted within 60 calendar days of the award performance end date. Final payment is contingent upon receipt and approval of the Final Report.
- Accelerator Award reporting requirements: The PI shall submit an Annual Technical Progress Report within 15 calendar days of the anniversary of the award, followed by a Final Technical Report. The Final Technical Report shall be submitted within 60 calendar days of the award performance end date. Final payment is contingent upon receipt and approval of the Final Report.
Invention Disclosure: Institutions awarded TRISH funding must report each invention disclosure or patent application resulting from their TRISH research grant to both TRISH and NASA within 60 days of investigator disclosure to the home institution.
For NASA: Submit either a hard copy of Form 1679 to NASA Innovative Partnerships Office, Mail Code AF2, 2101 NASA Parkway, Houston, TX 77058 OR submit online. In the field designating contract number, please cite NNX16AO69A.
For TRISH: In addition to reporting on intellectual property on the annual project report, please also send copies of the institutional invention disclosure AND NASA Form 1679 or the summary from the online disclosure via email to email@example.com.
Publications: For TRISH-funded research, please clearly identify support received from TRISH in all publications, invention disclosures, copyrights and patents, using the following phrase: “This work is supported by the Translational Research Institute through NASA Cooperative Agreement NNX16AO69A.
Please note that prior to submission for publication, any research publications or presentations utilizing research data from Life Sciences Data Archive (LSDA) or crew medical data from Lifetime Surveillance of Astronaut Health must be submitted to the organization that supplied the data for review to ensure that no personally identifiable information data is included. In addition, recognition of either or both of these data sources must be included in the publication’s or presentation’s acknowledgments section if not otherwise included in the document.
TRISH-funded authors and co-authors will be required to deposit copies of their peer-reviewed scientific publications and associated data into NASA’s publication repository called NASA PubSpace, managed by the NIH’s PubMed Central. This excludes patents, publications that contain material governed by personal privacy, export control, proprietary restrictions, or national security law or regulations.
Note that this solicitation is being administered by CIMIT in support of TRISH